News Daily News Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk Michael O'Riordan December 03, 2019
News Conference News AHA 2019 Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial Shelley Wood November 18, 2019
News Conference News AHA 2019 COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine Caitlin E. Cox November 16, 2019
News Daily News Recurrent Events Common Among Young Patients With CAD Michael O'Riordan October 11, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2019 Shelley Wood October 01, 2019
News Conference News ESC 2019 Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events Michael O'Riordan September 02, 2019
News Daily News PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years Todd Neale August 23, 2019
News Daily News Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients Michael O'Riordan August 22, 2019
News Daily News High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk Michael O'Riordan July 01, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Daily News Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events Michael O'Riordan April 18, 2019
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Daily News Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests Michael O'Riordan February 08, 2019
News Daily News Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests Todd Neale February 01, 2019
News Daily News Gasp! Cardiorespiratory Fitness Falling Over Time, Duke Study Suggests Michael O'Riordan January 23, 2019
News Daily News Dose-Response Benefits for Fiber Intake Seen Across Wide Swath of Acquired Diseases Shelley Wood January 15, 2019
News Daily News Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts Michael O'Riordan November 23, 2018
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Daily News ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom Michael O'Riordan November 07, 2018